Two Pediatric Osteosarcoma Cases with Delayed Methotrexate Excretion: Its Clinical Course and Management.
- Author:
Kang Min LEE
1
;
Hee Woo LEE
;
Seung Yeon KIM
;
Hyeon Jeong LEE
;
Dong Hwan KIM
;
Joongbum CHO
;
Dong Ho KIM
;
Jung Sub LIM
;
Jin Kyung LEE
;
Jun Ah LEE
Author Information
1. Department of Pediatrics, Korea Cancer Center Hospital, Seoul, Korea. junahlee@kcch.re.kr
- Publication Type:Case Report
- Keywords:
Methotrexate;
Osteosarcoma;
Child;
Complication;
Management
- MeSH:
Child;
Hospitalization;
Humans;
Leucovorin;
Methotrexate;
Osteosarcoma;
Renal Dialysis
- From:Cancer Research and Treatment
2011;43(1):67-70
- CountryRepublic of Korea
- Language:English
-
Abstract:
High-dose methotrexate (MTX) chemotherapy extends the duration of hospitalization and introduces the risks of serious complications related to delayed MTX excretion. The treatment of delayed MTX excretion is largely dependent on invasive measures such as hemodialysis because the clinical data regarding the efficacy or safety of carboxypetidase G2 is limited. We report here on the cases of two pediatric osteosarcoma patients with delayed MTX excretion and who were successfully managed using supportive measures. Potential life-threatening complications were prevented by administering high doses of leucovorin.
